Comprehensive analysis of constitutional mismatch repair deficiency-associated non-Hodgkin lymphomas in a global cohort - UNICANCER
Article Dans Une Revue Pediatric Blood and Cancer Année : 2024

Comprehensive analysis of constitutional mismatch repair deficiency-associated non-Hodgkin lymphomas in a global cohort

Victoria J. Forster
  • Fonction : Auteur
Vanessa Bianchi
  • Fonction : Auteur
Melissa Edwards
  • Fonction : Auteur
Hiba Al-Tarrah
  • Fonction : Auteur
Uri Tabori
  • Fonction : Auteur
Andishe Attarbaschi
  • Fonction : Auteur
Amos Burke
  • Fonction : Auteur
Birgit Burkhardt
  • Fonction : Auteur
Anne Kathrin Garthe
  • Fonction : Auteur
Christine Devalck
  • Fonction : Auteur
Sarah Elitzur
  • Fonction : Auteur
Yael Goldberg
  • Fonction : Auteur
Sukanya Horpaopan
  • Fonction : Auteur
Katharina Wimmer
  • Fonction : Auteur
Edita Kabíčková
  • Fonction : Auteur
Christian P. Kratz
  • Fonction : Auteur
Jan Loeffen
  • Fonction : Auteur
Vanessa Pérez-Alonso
  • Fonction : Auteur
Marta Pineda
  • Fonction : Auteur
Daniel Rueda
  • Fonction : Auteur
Clara Ruiz-Ponte
  • Fonction : Auteur
Amelie Trinquand
  • Fonction : Auteur
Anne Uyttebroeck
  • Fonction : Auteur

Résumé

Constitutional mismatch repair deficiency syndrome (CMMRD) is a rare childhood cancer predisposition syndrome associated with a broad spectrum of malignancies, including non-Hodgkin lymphomas (NHL). Most patients die due to cancer before the age of 20 years. Limited data exist on CMMRD-associated lymphomas and their outcome. Methods: We conducted a retrospective study including all CMMRD-associated NHL patients registered before 2020 in the European and North American databases or reported by members of the European Intergroup for Childhood Non-Hodgkin Lymphoma (EICNHL). Events considered to define event-free survival included relapse/progression, second malignancy (SML), or death, whichever occurred first. Findings: The analysis included 74 patients, with 20 having multiple metachronous NHL. The median age at diagnosis was 9.4 years. Previous malignancies were reported in 36% of the patients, café au lait spots in 96%, and consanguinity in 54%. The initial lymphoma subtypes were 53 T-cell lymphoblastic lymphomas (T-LBL), four B-lymphoblastic lymphomas, and 17 mature B-cell non-Hodgkin lymphoma (B-NHL). All patients were treated with curative intent, with current chemotherapy regimens adapted to their subtype. The median follow-up was 8.7 years. After the first lymphoma, the 5-year event-free and overall survival rates were, respectively, 23.5% [95% confidence interval (CI): 14.9u201335.1] and 61.5% [95% CI: 49.6u201372.1]. The 5-year cumulative risk of progression/relapse, SML or death as a first event was 20.8%, 52.9%, and 2.7%. Interpretation: Standard treatments for sporadic NHL are effective in most CMMRD-associated NHL cases, but multiple malignancies, including lymphomas, impair prognosis. Future strategies should evaluate the potential of less genotoxic therapies, including immunotherapy, in preventing SMLs while maintaining effective control of NHL.
Fichier principal
Vignette du fichier
Pediatric Blood Cancer - 2024 - Rigaud - Comprehensive analysis of constitutional mismatch repair deficiency‐associated.pdf (1.41 Mo) Télécharger le fichier
Origine Publication financée par une institution
licence

Dates et versions

hal-04724649 , version 1 (31-10-2024)

Licence

Identifiants

Citer

Charlotte Rigaud, Léa Guerrini-Rousseau, Véronique Minard-Colin, Laurence Brugieres, Victoria J. Forster, et al.. Comprehensive analysis of constitutional mismatch repair deficiency-associated non-Hodgkin lymphomas in a global cohort. Pediatric Blood and Cancer, 2024, ⟨10.1002/pbc.31302⟩. ⟨hal-04724649⟩
4 Consultations
0 Téléchargements

Altmetric

Partager

More